WO2012066502A1 - Processes for preparation of everolimus and intermediates thereof - Google Patents
Processes for preparation of everolimus and intermediates thereof Download PDFInfo
- Publication number
- WO2012066502A1 WO2012066502A1 PCT/IB2011/055156 IB2011055156W WO2012066502A1 WO 2012066502 A1 WO2012066502 A1 WO 2012066502A1 IB 2011055156 W IB2011055156 W IB 2011055156W WO 2012066502 A1 WO2012066502 A1 WO 2012066502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- butyldimethylsilyl
- everolimus
- sirolimus
- oxy
- ethyl rapamycin
- Prior art date
Links
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title claims abstract description 55
- 229960005167 everolimus Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 50
- 239000000543 intermediate Substances 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 117
- 229960002930 sirolimus Drugs 0.000 claims abstract description 117
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 63
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000011347 resin Substances 0.000 claims abstract description 9
- 229920005989 resin Polymers 0.000 claims abstract description 9
- -1 ethyl rapamycin Chemical compound 0.000 claims description 91
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 63
- DUUWFQBUGWHIMO-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethyl trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OCCOS(=O)(=O)C(F)(F)F DUUWFQBUGWHIMO-UHFFFAOYSA-N 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 25
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- GDAUFPWBWODYJZ-UHFFFAOYSA-N 1-[tert-butyl(dimethyl)silyl]ethane-1,2-diol Chemical compound CC(C)(C)[Si](C)(C)C(O)CO GDAUFPWBWODYJZ-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 229940093499 ethyl acetate Drugs 0.000 claims description 6
- 235000019439 ethyl acetate Nutrition 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 150000007517 lewis acids Chemical class 0.000 claims description 3
- 150000007530 organic bases Chemical group 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 25
- 238000007792 addition Methods 0.000 abstract description 14
- 238000005580 one pot reaction Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 239000012044 organic layer Substances 0.000 description 26
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 230000001861 immunosuppressant effect Effects 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UVECLJDRPFNRRQ-UHFFFAOYSA-N ethyl trifluoromethanesulfonate Chemical compound CCOS(=O)(=O)C(F)(F)F UVECLJDRPFNRRQ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 229940043785 zortress Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
Definitions
- the present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion and resin mediated synthesis.
- Everolimus (RAD-001) ( Figure 1) is an immunosuppressant semi-synthetic drug, marketed by Novartis under the trade names of Zortress ® (USA) and Certican ® (Europe and other countries) as transplantation medicine and as Afinitor ® in oncology.
- Everolimus is a derivative of Sirolimus (Rapamycin), works similarly to Sirolimus as an mTOR (mammalian target of rapamycin) inhibitor. It is mainly used as an immunosuppressant to prevent rejection in organ transplantation.
- Everolimus is also used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis.
- Everolimus is 40-O-(2-Hydroxy)ethyl rapamycin.
- FDA has approved Everolimus in March 2009 for the treatment of advanced kidney cancer, and for the organ rejection prophylaxis in April 2010.
- US 7,297,703 B2 disclosed the use of antioxidant such as 2,6-di-tert-butyl-4- methylphenol for improving the stability of poly-ene macrolides.
- US 7,297,703 B2 also disclosed substantially pure crystalline polymorph of Everolimus having m.p. 146.5 °C. For that amorphous Everolimus is converted into the crystalline form using ethyl acetate and heptane solvents. It is also mentioned that the crystalline form is non- solvate form.
- FIG 1 shows Everolimus an immunosuppressant semi-synthetic drug (Prior art).
- Figure 2 shows preparation processes of Everolimus and intermediates.
- Figure 3 shows preparation of Everolimus intermediate 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3).
- the present disclosure relates to a process for obtaining Everolimus, said process comprising acts of a) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to Sirolimus to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) and b) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) to obtain Everolimus; a process for obtaining Everolimus, said process comprising acts of a) adding Sirolimus to 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) and b) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapa
- the present disclosure relates to a process for obtaining Everolimus, said process comprising acts of:
- the present disclosure also relates to a process for obtaining Everolimus, said process comprising acts of:
- the present disclosure also relates to a process for obtaining Everolimus, said process comprising acts of:
- the present disclosure also relates to a process for obtaining Everolimus, said process comprising acts of: a) obtaining a mixture comprising 2-(-t-butyldimethylsilyl)oxyethyl triflate (2), 2-(t-butyldimethylsilyl) ethylene glycol (1), base and organic solvent, in any order thereof;
- the 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) is added in complete or portionwise, preferably in about 1.0 to about 10 .0 portions, more preferably in about 3.0 to about 5.0 portions.
- the Sirolimus is added in complete or portionwise, optionally in 1.0 to 10 .0 portions, preferably in 3.0 to 5.0 portions.
- the 2-(-t- butyldimethylsilyl)oxy ethyl triflate (2) is ranging from about 1 equivalent to about 35 equivalents, preferably about 2 equivalents to about 30 equivalents, more preferably about 4 equivalents to about 22 equivalents; and the Sirolimus is ranging from about 0.1 equivalent to about 1.Oequivalent.
- the Sirolimus is in form of solid or solution.
- the solid Sirolimus is added in amount ranging from about 25mg to about 5kg.
- the solution Sirolimus is added in amount ranging from about 25ml to about 5.0 Its.
- said process is carried out at temperature ranging from about -80 °C to about 70 °C, preferably from about -70 °C to about 55 °C, more preferably from about -45 °C to about 45 °C. In still another embodiment of the present disclosure, said process is carried out at time period ranging from about 5 minutes to about 24 hours, preferably from about 15 minutes to about 12 hours, more preferably from about 30 minutes to about 8 hours.
- the treating is carried out using methanol and cationic resin selected from group comprising SKI 10, UBK558 and T42H or lewis acid selected from group comprising BF3. Et20 and Zinc chroride; and organic acids selected from group comprising methanesulfonic acid, p-toluene sulfonic acid, Formic acid and dihydrochloric acid or any combination thereof.
- methanol and cationic resin selected from group comprising SKI 10, UBK558 and T42H or lewis acid selected from group comprising BF3.
- Et20 and Zinc chroride and organic acids selected from group comprising methanesulfonic acid, p-toluene sulfonic acid, Formic acid and dihydrochloric acid or any combination thereof.
- the purifying is carried out using chromatography or lyophilisation.
- the base is organic base selected from group comprising 2,6-Lutidine, pyridine, triethylamine, diisopropylamine, and diisopropylethylamine in amount ranging from about 2.0 eq to about 5.0 eq
- the solvent is organic solvent selected from group comprising Toluene, ethylacetate, Diisopropyl ether and halogenated solvent selected from group comprising dichloromethane and chloroform, or any combination thereof.
- the Everolimus has purity ranging from about 85% to about 99.9%, preferably from about 90%> to about 99.5%, more preferably from about 98% to about 99.2%.
- the Everolimus has yield ranging from about 75% to about 99%, preferably from about 80% to about 98%, more preferably from about 85% to about 95%.
- the present disclosure also discloses preparation processes of Everolimus: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and final resin mediated synthesis.
- Sirolimus Rosolimus
- Treatment of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) with solid Sirolimus under the solvent free conditions produced corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in reasonably good yield.
- the present disclosure discloses the preparation processes of Everolimus and intermediates using most efficient one pot, the solvent free, portion wise addition, reverse addition, solid phase, and resin mediated techniques of process chemistry.
- Everolimus intermediate 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) is prepared by following Figure 3.
- X sulfonate (triflate, mesylate, tosylate) or halogen (chlorine, bromine, iodine);
- P silyl protecting group (TMS, TES, TIPS, TBDMS, TBDPS).
- the most preferred base is 2,6-Lutidine; more preferred base is any organic base such as pyridine, triethylamine, diisopropylamine, diisopropylethylamine, etc.;
- the most preferred solvent is dichloromethane; more preferred solvent is any halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, etc.; preferred solvent is any organic solvent, and mixture thereof.
- the temperature range for the process is preferably from -80 °C to 70 °C; more preferably from -70 °C to 55 °C; most preferably from -45 °C to 45 °C.
- the equivalents of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) is preferably from 1 to 35, more preferably from 2 to 30, most preferably from 4 to 22.
- the reaction time is preferably from 5 minutes to 24h, more preferably 15 minutes to 12h, most preferably 0.5h to 8h.
- Evelorimus is synthesized by cleaving the silyl protecting of structure II of figure 3, for instance 40- 0-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) by a cationic resin such as SKI 10, UBK558, T42H or by lewis acid such as BF 3 . Et 2 0, Zinc chloride etc.
- Example 4 r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
- 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq)
- Ethyl acetate (3 vol)
- solid Sirolimus 25g
- the resulting mixture is stirred at 45-50°C till completion of the reaction, quenched, and organic layer is separated.
- the resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 35% yield.
- Example 13 40-0-l2-(t-butyldimethylsilyl)oxy1 ethyl rapamycin (3)1
- 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (8 eq) in 2,6-Lutidine (3.0 eq), and dichloromethane (3 vol)
- 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (8 eq) in 2,6-Lutidine (3.0 eq), and dichloromethane (3 vol) is added in three portions to three lots of solid Sirolimus (each lot 5.0g) (25g).
- the resulting mixture is stirred till completion of the reaction, quenched, and separated the organic layer.
- the resulting organic layer is purified to obtain corresponding 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) in 50 % yield.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and resin mediated synthesis.
Description
"PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF"
TECHNICAL FIELD
The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion and resin mediated synthesis.
BACKGROUND AND PRIOR ART OF THE DISCLOSURE
Everolimus (RAD-001) (Figure 1) is an immunosuppressant semi-synthetic drug, marketed by Novartis under the trade names of Zortress® (USA) and Certican® (Europe and other countries) as transplantation medicine and as Afinitor® in oncology. Everolimus is a derivative of Sirolimus (Rapamycin), works similarly to Sirolimus as an mTOR (mammalian target of rapamycin) inhibitor. It is mainly used as an immunosuppressant to prevent rejection in organ transplantation. Everolimus is also used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Structurally, Everolimus is 40-O-(2-Hydroxy)ethyl rapamycin. FDA has approved Everolimus in March 2009 for the treatment of advanced kidney cancer, and for the organ rejection prophylaxis in April 2010.
The structure and synthesis of Everolimus [40-O-(2-Hydroxy)ethyl rapamycin] and its use as an immunosuppressant was first described in US 5,665,772 along with other novel Rapamycin derivatives. For the synthesis, firstly Ramapycin and 2-(t- butyldimethylsilyl)oxyethyl triflate are reacted in presence of 2,6-Lutidine in toluene at around 60 °C to obtain corresponding 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin, which then converted into Everolimus [40-O-(2-Hydroxy)ethyl rapamycin]. However, the conversion resulted in very poor overall yield.
US 7,297,703 B2 disclosed the use of antioxidant such as 2,6-di-tert-butyl-4- methylphenol for improving the stability of poly-ene macrolides. US 7,297,703 B2 also disclosed substantially pure crystalline polymorph of Everolimus having m.p. 146.5 °C. For that amorphous Everolimus is converted into the crystalline form using ethyl
acetate and heptane solvents. It is also mentioned that the crystalline form is non- solvate form.
BRIEF DESCRIPTION OF THE ACCOMPANYING FIGURES
In order that the disclosure may be readily understood and put into practical effect, reference will now be made to exemplary embodiments as illustrated with reference to the accompanying figures. The figure together with a detailed description below, are incorporated in and form part of the specification, and serve to further illustrate the embodiments and explain various principles and advantages, in accordance with the present disclosure where:
Figure 1 shows Everolimus an immunosuppressant semi-synthetic drug (Prior art). Figure 2 shows preparation processes of Everolimus and intermediates.
Figure 3 shows preparation of Everolimus intermediate 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3).
STATEMENT OF THE DISCLOSURE
Accordingly, the present disclosure relates to a process for obtaining Everolimus, said process comprising acts of a) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to Sirolimus to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) and b) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) to obtain Everolimus; a process for obtaining Everolimus, said process comprising acts of a) adding Sirolimus to 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) and b) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) to obtain Everolimus; a process for obtaining Everolimus, said process comprising acts of a) obtaining a mixture comprising Sirolimus, 2-(t-butyldimethylsilyl) ethylene glycol (1), base and organic solvent, in any order thereof, b) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to the mixture to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) and c) treating and purifying the crude 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) to obtain Everolimus; and a process for obtaining Everolimus, said process comprising acts of a) obtaining a mixture comprising 2-(-t-butyldimethylsilyl)oxyethyl triflate (2), 2-(t-butyldimethylsilyl)
ethylene glycol (1), base and organic solvent, in any order thereof, b) adding Sirolimus to the mixture to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) and c) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
DETAILED DESCRIPTION OF THE DISCLOSURE
The present disclosure relates to a process for obtaining Everolimus, said process comprising acts of:
a) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to Sirolimus to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3); and b) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
The present disclosure also relates to a process for obtaining Everolimus, said process comprising acts of:
a) adding Sirolimus to 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3); and b) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
The present disclosure also relates to a process for obtaining Everolimus, said process comprising acts of:
a) obtaining a mixture comprising Sirolimus, 2-(t-butyldimethylsilyl) ethylene glycol (1), base and organic solvent, in any order thereof;
b) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to the mixture to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3); and c) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus. The present disclosure also relates to a process for obtaining Everolimus, said process comprising acts of:
a) obtaining a mixture comprising 2-(-t-butyldimethylsilyl)oxyethyl triflate (2), 2-(t-butyldimethylsilyl) ethylene glycol (1), base and organic solvent, in any order thereof;
b) adding Sirolimus to the mixture to obtain crude 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3); and
c) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
In an embodiment of the present disclosure, wherein the 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) is added in complete or portionwise, preferably in about 1.0 to about 10 .0 portions, more preferably in about 3.0 to about 5.0 portions.
In another embodiment of the present disclosure, the Sirolimus is added in complete or portionwise, optionally in 1.0 to 10 .0 portions, preferably in 3.0 to 5.0 portions.
In yet another embodiment of the present disclosure, the 2-(-t- butyldimethylsilyl)oxy ethyl triflate (2) is ranging from about 1 equivalent to about 35 equivalents, preferably about 2 equivalents to about 30 equivalents, more preferably about 4 equivalents to about 22 equivalents; and the Sirolimus is ranging from about 0.1 equivalent to about 1.Oequivalent.
In still another embodiment of the present disclosure, the Sirolimus is in form of solid or solution.
In still another embodiment of the present disclosure, the solid Sirolimus is added in amount ranging from about 25mg to about 5kg.
In still another embodiment of the present disclosure, the solution Sirolimus is added in amount ranging from about 25ml to about 5.0 Its.
In still another embodiment of the present disclosure, said process is carried out at temperature ranging from about -80 °C to about 70 °C, preferably from about -70 °C to about 55 °C, more preferably from about -45 °C to about 45 °C.
In still another embodiment of the present disclosure, said process is carried out at time period ranging from about 5 minutes to about 24 hours, preferably from about 15 minutes to about 12 hours, more preferably from about 30 minutes to about 8 hours.
In still another embodiment of the present disclosure, the treating is carried out using methanol and cationic resin selected from group comprising SKI 10, UBK558 and T42H or lewis acid selected from group comprising BF3. Et20 and Zinc chroride; and organic acids selected from group comprising methanesulfonic acid, p-toluene sulfonic acid, Formic acid and dihydrochloric acid or any combination thereof.
In still another embodiment of the present disclosure, the purifying is carried out using chromatography or lyophilisation. In still another embodiment of the present disclosure, the base is organic base selected from group comprising 2,6-Lutidine, pyridine, triethylamine, diisopropylamine, and diisopropylethylamine in amount ranging from about 2.0 eq to about 5.0 eq
In still another embodiment of the present disclosure, the solvent is organic solvent selected from group comprising Toluene, ethylacetate, Diisopropyl ether and halogenated solvent selected from group comprising dichloromethane and chloroform, or any combination thereof.
In still another embodiment of the present disclosure, the Everolimus has purity ranging from about 85% to about 99.9%, preferably from about 90%> to about 99.5%, more preferably from about 98% to about 99.2%.
In still another embodiment of the present disclosure, the Everolimus has yield ranging from about 75% to about 99%, preferably from about 80% to about 98%, more preferably from about 85% to about 95%.
The present disclosure also discloses preparation processes of Everolimus: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and final resin mediated synthesis. Surprisingly, treatment of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) with solid Sirolimus under the solvent free conditions produced corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in reasonably good yield. Further modification of the reaction conditions, such as the portion wise addition of the 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) to the solid sirolimus and / or vice versa produced the corresponding product 3 in improved yields and reactions conditions. Addition of the 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) mixture directly to the solid Sirolimus is similar to solid phase and reverse addition techniques, which are very familiar in the synthetic chemistry (Figure 2). More interestingly, direct addition of triflic anhydride to the mixture of Sirolimus, 2-(t- butyldimethylsilyl) ethylene glycol (1), and a base such as 2,6-Lutidine in an organic solvent such as dichloromethane under one pot condition produced the corresponding 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3). The final deprotection of t- butyldimethylsilyl ether of 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) is achieved using acidic resin to produce Everolimus in excellent conversion (>90%) overall. The present disclosure discloses the preparation processes of Everolimus and intermediates using most efficient one pot, the solvent free, portion wise addition, reverse addition, solid phase, and resin mediated techniques of process chemistry. According to the depicted embodiments of the present disclosure, Everolimus intermediate 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) is prepared by following Figure 3.
In Figure 3, particularly in structure I, X = leaving group, P = protecting group.
More precisely, X = sulfonate (triflate, mesylate, tosylate) or halogen (chlorine, bromine, iodine); P = silyl protecting group (TMS, TES, TIPS, TBDMS, TBDPS).
According to the depicted embodiments of the present disclosure, Everolimus intermediate 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) is prepared by following (where in X = O-trifate and P = O-TBDMS):
i) complete / portion wise addition of the 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to Sirolimus solid / solution.
ii) complete / portion wise addition of the 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) containing a base such as 2,6-Lutidine, and an organic solvent such as dichloromethane to solid Sirolimus solid / solution.
iii) complete / portion wise addition of the Sirolimus solid / solution to the 2-(-t- butyldimethylsilyl)oxy ethyl triflate (2).
iv) complete / portion wise addition of the Sirolimus solid / solution to the 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) containing a base such as 2,6-Lutidine, and an organic solvent such as dichloromethane ,Ethylacetate, Toluene etc.
v) complete / portion wise addition of triflic anhydride to the mixtrure of Sirolimus, 2- (t-butyldimethylsilyl) ethylene glycol (1), and a base such as 2,6-Lutidine in an organic solvent such as dichloromethane under one pot condition.
The most preferred base is 2,6-Lutidine; more preferred base is any organic base such as pyridine, triethylamine, diisopropylamine, diisopropylethylamine, etc.;
The most preferred solvent is dichloromethane; more preferred solvent is any halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, etc.; preferred solvent is any organic solvent, and mixture thereof. The temperature range for the process is preferably from -80 °C to 70 °C; more preferably from -70 °C to 55 °C; most preferably from -45 °C to 45 °C.
The equivalents of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) is preferably from 1 to 35, more preferably from 2 to 30, most preferably from 4 to 22. The reaction time is preferably from 5 minutes to 24h, more preferably 15 minutes to 12h, most preferably 0.5h to 8h.
According to the depicted embodiments of the present disclosure, Evelorimus is synthesized by cleaving the silyl protecting of structure II of figure 3, for instance 40- 0-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) by a cationic resin such as SKI 10, UBK558, T42H or by lewis acid such as BF3. Et20, Zinc chloride etc.
According to the depicted embodiments of the present disclosure, pure Everolimus is isolated by HPLC and lyophilisation.
The present disclosure is further elaborated by the following examples and figures. However, these examples should not be construed to limit the scope of the disclosure.
EXAMPLES
Example 1: r40-O-r2-(t-butyldimethylsilyl)oxy1 ethyl rapamycin (3)1
To the solid Sirolimus (25 g), is added freshly prepared solution of 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq), and dichloromethane (3.0 vol) at room temperature. The resulting mixture is stirred till completion of the reaction, quenched, and the organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 35% yield. Example 2: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the mixture of Sirolmus (25g) (1 eq), 2-(t-butyldimethylsilyl) ethylene glycol (5 eq), 2,6-Lutidine (2.2 eq) in dichloromethane (3 vol) in one pot condition, is added triflic anhydride ( 5eq) and stirred. After the completion of the reaction, the crude product is isolated by chromatographic purification as a syrup in more than 30% yield.
Example 3: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl) oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq), and dichloromethane (3 vol), is added solid Sirolimus (25g). The resulting mixture is stirred till completion of the reaction, quenched, and separated the organic layer. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 45% yield.
Example 4: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq), and Ethyl acetate (3 vol), is added solid Sirolimus (25g). The resulting mixture is stirred at 45-50°C till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 35% yield.
Example 5: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq), and dichloromethane (3 vol), is added solid Sirolimus (25g). The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 45% yield.
Example 6: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq), and Toluene (3 vol), is added solid Sirolimus (25g). The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 30% yield.
Example 7: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (2 eq), and dichloromethane (3 vol), is added solid Sirolimus (25g). The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 45% yield.
Example 8: r40-O-r2-(t-butyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (8 eq) in 2,6-Lutidine (3.0 eq), and dichloromethane (3 vol), is added solid Sirolimus (25g). The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 40 % yield.
Example 9: 40-0 2-(t )utyldimethylsilyl)oxy1ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (8 eq) in 2,6-Lutidine (3.0 eq), and dichloromethane (3 vol), is added in three portions to solid Sirolimus (25g). The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) in 50 % yield.
Example 10: r40-O-r2-(t-butyldimethylsilyl)oxy1 ethyl rapamycin (3)1
To a solution of Sirolimus (25g) in Dichloromethane (25ml), is added a freshly prepared solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (4 eq) in 2,6-Lutidine (3.0 eq), and dichloromethane (3.0 vol) at room temperature. The resulting mixture is stirred at reflux temperature till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 25% yield.
Example 11: 40-0-l2-(t-butyldimethylsilyl)oxy1 ethyl rapamycin (3)1
To the solid Sirolimus (25 g), is added freshly prepared solution of 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) (4.0 eq) in 2,6-Lutidine (2.5 eq), and dichloromethane (3.0 vol) at room temperature. The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 35% yield. Example 12: 40-0-l2-(t-butyldimethylsilyl)oxy1 ethyl rapamycin (3)1
To the solid Sirolimus (25 g), is added freshly prepared solution of 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) (8.0 eq) and 2,6-Lutidine (3.0eq), and dichloromethane (3.0 vol) at room temperature in five lots. The resulting mixture is stirred till completion of the reaction, quenched, and organic layer is separated. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3) in 40 % yield.
Example 13: 40-0-l2-(t-butyldimethylsilyl)oxy1 ethyl rapamycin (3)1
To the solution of 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) (8 eq) in 2,6-Lutidine (3.0 eq), and dichloromethane (3 vol), is added in three portions to three lots of solid Sirolimus (each lot 5.0g) (25g). The resulting mixture is stirred till completion of the reaction, quenched, and separated the organic layer. The resulting organic layer is purified to obtain corresponding 40-O-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) in 50 % yield.
Example 14: r40-O-(2-Hvdroxy)ethyl rapamycinl
To the solution of 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) (30g) in methanol (5 vol), is added cationic resin (10% wt/wt) and stirred till the completion of the reaction. Pure product (Everolimus) having about 99.2% purity is isolated from the crude by HPLC purification in >90%> yield.
Example 15: [40-O-r2-(t-butvldimethylsilvl)oxv1 ethyl rapamycin (3)]
To the solution of 2-(t-butyl dimethysilyloxy)ethyl triflate (2) (8.0 eq) in 2,6-lutidine (2.5 eq) and Dichloromethane(2.0 vol) is added Solid Sirolimus (5.0 kg).The resulting mixture is stirred till completion of the reaction, quenched and the organic layer is separated. The crude product is isolated by chromatographic purification to get pure 40- 0-[2-(t-butyldimethylsilyl)oxy] ethyl rapamycin (3) as foam in 45 % yield . Example 16: [40-rO-r2-(t-butvldimethvlsilvl)oxv1ethyl rapamycin (3)]
To the solution of 40-[O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) (2.25 kg) in methanol (10 vol) is added 1.0 N HCl (2.0 vol). and stirred till completion of the reaction. After reaction completion the reaction mass is partitioned between water and ethylacetate. The organic layer is dried over Sodium Sulphate and evaporated under reduced pressure dryness which is further purified by HPLC purification to get pure Everolimus as a white solid (300-350g) with purity more than 98% in greater than 85% yield.
Claims
A process for obtaining Everolimus, said process comprising acts of:
c) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to Sirolimus to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3); and d) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
A process for obtaining Everolimus, said process comprising acts of:
c) adding Sirolimus to 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3); and d) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
A process for obtaining Everolimus, said process comprising acts of:
d) obtaining a mixture comprising Sirolimus, 2-(t-butyldimethylsilyl) ethylene glycol (1), base and organic solvent, in any order thereof;
e) adding 2-(-t-butyldimethylsilyl)oxyethyl triflate (2) to the mixture to obtain crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3); and f) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
A process for obtaining Everolimus, said process comprising acts of:
d) obtaining a mixture comprising 2-(-t-butyldimethylsilyl)oxyethyl triflate (2), 2-(t-butyldimethylsilyl) ethylene glycol (1), base and organic solvent, in any order thereof;
e) adding Sirolimus to the mixture to obtain crude 40-O-[2-(t- butyldimethylsilyl)oxy] ethyl rapamycin (3); and
f) treating and purifying the crude 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin (3) to obtain Everolimus.
The process as claimed in claims 1 and 3, wherein the 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) is added in complete or portionwise, preferably in about 1.0 to about 10 .0 portions, more preferably in about 3.0 to about 5.0 portions.
6. The process as claimed in claims 2 and 4, wherein the Sirolimus is added in complete or portionwise, optionally in 1.0 to 10 .0 portions, preferably in 3.0 to 5.0 portions.
7. The process as claimed in claims 1 to 4, wherein the 2-(-t- butyldimethylsilyl)oxyethyl triflate (2) is ranging from about 1 equivalent to about 35 equivalents, preferably about 2 equivalents to about 30 equivalents, more preferably about 4 equivalents to about 22 equivalents; and the Sirolimus is ranging from about 0.1 equivalent to about l .Oequivalent.
8. The process as claimed in claims 1 to 4, wherein the Sirolimus is in form of solid or solution.
9. The process as claimed in claim 8, wherein the solid Sirolimus is added in amount ranging from about 25mg to about 5kg.
10. The process as claimed in claim 8, wherein the solution Sirolimus is added in amount ranging from about 25ml to about 5.0 Its.
11. The process as claimed in claims 1 to 4, wherein said process is carried out at temperature ranging from about -80 °C to about 70 °C, preferably from about - 70 °C to about 55 °C, more preferably from about -45 °C to about 45 °C.
12. The process as claimed in claims 1 to 4, wherein said process is carried out at time period ranging from about 5 minutes to about 24 hours, preferably from about 15 minutes to about 12 hours, more preferably from about 30 minutes to about 8 hours.
13. The process as claimed in claims 1 to 4, wherein the treating is carried out using methanol and cationic resin selected from group comprising SKI 10, UBK558 and T42H or lewis acid selected from group comprising BF3. Et20 and Zinc chroride; and organic acids selected from group comprising methanesulfonic acid, p-toluene sulfonic acid, Formic acid and dihydrochloric acid or any combination thereof.
14. The process as claimed in claims 1 to 4, wherein the purifying is carried out using chromatography or lyophilisation.
15. The process as claimed in claims 3 and 4, wherein the base is organic base selected from group comprising 2,6-Lutidine, pyridine, triethylamine, diisopropylamine, and diisopropylethylamine in amount ranging from about 2.0 eq to about 5.0 eq
16. The process as claimed in claims 3 and 4, wherein the solvent is organic solvent selected from group comprising Toluene, ethylacetate, Diisopropyl ether and halogenated solvent selected from group comprising dichloromethane and chloroform, or any combination thereof.
17. The process as claimed in claims 1 to 4, wherein the Everolimus has purity ranging from about 85% to about 99.9%, preferably from about 90%> to about 99.5%), more preferably from about 98%> to about 99.2%>.
18. The process as claimed in claims 1 to 4, wherein the Everolimus has yield ranging from about 75% to about 99%, preferably from about 80%> to about 98%), more preferably from about 85% to about 95%.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2818225A CA2818225C (en) | 2010-11-19 | 2011-11-17 | Processes for preparation of everolimus and intermediates thereof |
EP11841039.8A EP2640730B1 (en) | 2010-11-19 | 2011-11-17 | Processes for preparation of everolimus and intermediates thereof |
ES11841039T ES2753529T3 (en) | 2010-11-19 | 2011-11-17 | Processes for the preparation of everolimus and intermediate products thereof |
US13/988,265 US9079921B2 (en) | 2010-11-19 | 2011-11-17 | Processes for preparation of Everolimus and intermediates thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3485CH2010 | 2010-11-19 | ||
IN3485/CHE/2010 | 2010-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012066502A1 true WO2012066502A1 (en) | 2012-05-24 |
Family
ID=46083548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/055156 WO2012066502A1 (en) | 2010-11-19 | 2011-11-17 | Processes for preparation of everolimus and intermediates thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US9079921B2 (en) |
EP (1) | EP2640730B1 (en) |
CA (1) | CA2818225C (en) |
ES (1) | ES2753529T3 (en) |
WO (1) | WO2012066502A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103360411A (en) * | 2013-07-17 | 2013-10-23 | 成都雅途生物技术有限公司 | Everolimus crystallization purification method |
WO2014116611A1 (en) * | 2013-01-22 | 2014-07-31 | Biosensors International Group, Ltd. | Low temperature synthesis of rapamycin derivatives |
WO2014203185A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Alkylation with an alkyl fluoroalkyl sulfonate |
CN104478898A (en) * | 2014-11-18 | 2015-04-01 | 连云港恒运医药科技有限公司 | Preparation method of everolimus and intermediate of everolimus |
CN104557975A (en) * | 2014-12-23 | 2015-04-29 | 连云港恒运医药科技有限公司 | Methods for preparing everolimus intermediates and everolimus degradation impurities |
CN104592254A (en) * | 2015-02-08 | 2015-05-06 | 福建省微生物研究所 | Synthesis method for everolimus |
CN105254646A (en) * | 2014-05-28 | 2016-01-20 | 上海博邦医药科技有限公司 | Everolimus preparation method |
CN105566348A (en) * | 2015-12-31 | 2016-05-11 | 哈药集团技术中心 | Preparation method of everolimus |
EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
US10117945B2 (en) | 2014-09-11 | 2018-11-06 | The Regents Of The University Of California | mTORC1 inhibitors |
CN109369680A (en) * | 2018-12-24 | 2019-02-22 | 江苏卓和药业有限公司 | A kind of purification process of everolimus |
US10980889B1 (en) | 2018-05-01 | 2021-04-20 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
US12097262B2 (en) | 2023-02-28 | 2024-09-24 | The Regents Of The University Of California | mTORC1 inhibitors |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106153756B (en) * | 2015-04-25 | 2020-04-28 | 山东新时代药业有限公司 | High performance liquid chromatography for detecting rapamycin in everolimus |
CN114539288B (en) * | 2020-11-24 | 2024-01-30 | 鲁南制药集团股份有限公司 | Preparation method of everolimus |
CN114671890B (en) * | 2020-12-24 | 2024-03-15 | 鲁南制药集团股份有限公司 | Efficient and stable everolimus preparation method |
CN115028658A (en) * | 2022-07-06 | 2022-09-09 | 国药集团川抗制药有限公司 | Rapamycin silanol ester and preparation method and application thereof |
CN116813641A (en) * | 2023-06-09 | 2023-09-29 | 杭州华东医药集团康润制药有限公司 | Preparation method of everolimus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9826882D0 (en) | 1998-12-07 | 1999-01-27 | Novartis Ag | Organic compounds |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
-
2011
- 2011-11-17 CA CA2818225A patent/CA2818225C/en active Active
- 2011-11-17 WO PCT/IB2011/055156 patent/WO2012066502A1/en active Application Filing
- 2011-11-17 EP EP11841039.8A patent/EP2640730B1/en active Active
- 2011-11-17 ES ES11841039T patent/ES2753529T3/en active Active
- 2011-11-17 US US13/988,265 patent/US9079921B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014116611A1 (en) * | 2013-01-22 | 2014-07-31 | Biosensors International Group, Ltd. | Low temperature synthesis of rapamycin derivatives |
CN105102463B (en) * | 2013-01-22 | 2017-05-31 | 生物传感器国际集团有限公司 | The low temperature synthesis of rapamycin derivative |
US9434744B2 (en) | 2013-01-22 | 2016-09-06 | Biosensors International Group, Ltd. | Low temperature synthesis of rapamycin derivatives |
CN105102463A (en) * | 2013-01-22 | 2015-11-25 | 生物传感器国际集团有限公司 | Low temperature synthesis of rapamycin derivatives |
JP2016505048A (en) * | 2013-01-22 | 2016-02-18 | バイオセンサーズ インターナショナル グループ、リミテッド | Low temperature synthesis of rapamycin derivatives |
JP2016523246A (en) * | 2013-06-20 | 2016-08-08 | ノバルティス アーゲー | Alkylation with alkyl fluoroalkyl sulfonates |
WO2014203185A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Alkylation with an alkyl fluoroalkyl sulfonate |
CN103360411A (en) * | 2013-07-17 | 2013-10-23 | 成都雅途生物技术有限公司 | Everolimus crystallization purification method |
CN105254646A (en) * | 2014-05-28 | 2016-01-20 | 上海博邦医药科技有限公司 | Everolimus preparation method |
US10646577B2 (en) | 2014-09-11 | 2020-05-12 | The Regents Of The University Of California | mTORC1 inhibitors |
US10117945B2 (en) | 2014-09-11 | 2018-11-06 | The Regents Of The University Of California | mTORC1 inhibitors |
US11452780B2 (en) | 2014-09-11 | 2022-09-27 | The Regents Of The University Of California | Mtorc1 inhibitors |
CN104478898A (en) * | 2014-11-18 | 2015-04-01 | 连云港恒运医药科技有限公司 | Preparation method of everolimus and intermediate of everolimus |
CN104557975B (en) * | 2014-12-23 | 2017-06-20 | 连云港恒运医药有限公司 | The preparation method of everolimus intermediate and its degradation impurity |
CN104557975A (en) * | 2014-12-23 | 2015-04-29 | 连云港恒运医药科技有限公司 | Methods for preparing everolimus intermediates and everolimus degradation impurities |
CN104592254A (en) * | 2015-02-08 | 2015-05-06 | 福建省微生物研究所 | Synthesis method for everolimus |
KR20180015257A (en) * | 2015-06-23 | 2018-02-12 | 신바이어스 파마 아게 | Method for the synthesis of rapamycin derivatives |
EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
KR102621941B1 (en) | 2015-06-23 | 2024-01-05 | 신바이어스 파마 아게 | Method for the synthesis of rapamycin derivatives |
CN105566348A (en) * | 2015-12-31 | 2016-05-11 | 哈药集团技术中心 | Preparation method of everolimus |
US10980889B1 (en) | 2018-05-01 | 2021-04-20 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11364300B2 (en) | 2018-05-01 | 2022-06-21 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
US12048749B2 (en) | 2018-05-01 | 2024-07-30 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
CN109369680A (en) * | 2018-12-24 | 2019-02-22 | 江苏卓和药业有限公司 | A kind of purification process of everolimus |
US12097262B2 (en) | 2023-02-28 | 2024-09-24 | The Regents Of The University Of California | mTORC1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA2818225A1 (en) | 2012-05-24 |
EP2640730A1 (en) | 2013-09-25 |
US20130225823A1 (en) | 2013-08-29 |
US9079921B2 (en) | 2015-07-14 |
EP2640730A4 (en) | 2014-07-09 |
ES2753529T3 (en) | 2020-04-13 |
EP2640730B1 (en) | 2019-08-07 |
CA2818225C (en) | 2016-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2640730B1 (en) | Processes for preparation of everolimus and intermediates thereof | |
US10450324B2 (en) | Methods useful in the synthesis of halichondrin B analogs | |
JP5202635B2 (en) | Processes and intermediates for the preparation of integrase inhibitors | |
JPH05163280A (en) | Bicyclic rapamycin | |
TW201130841A (en) | Process for preparing entecavir and its intermediates | |
WO2015019310A1 (en) | Process for the preparation of dolute-gravir and intermediates thereof | |
US20080097093A1 (en) | Processes for the synthesis of individual isomers of mono-peg CCI-779 | |
Bucciarelli et al. | Regioselectivity of ring-opening reactions of optically active N-acetyl-2-methoxycarbonylaziridine | |
EP3512835A1 (en) | A process for purification of carfilzomib intermediate | |
CN107827908B (en) | Rapamycin triazole derivative and preparation method and application thereof | |
WO2011051960A2 (en) | Process for the preparation of rapamycin derivatives | |
JP5492786B2 (en) | Intermediates and methods for making zeralenone macrolide analogs | |
AU2021300294A1 (en) | Methods and intermediates for preparing JAK inhibitors | |
SU786905A3 (en) | Method of preparing 17-beta-hydroxy-4-androsten-3-ones | |
WO2014116611A1 (en) | Low temperature synthesis of rapamycin derivatives | |
EA007222B1 (en) | Process for preparing acid salts of gemifloxacin | |
WO2023060022A1 (en) | Synthesis of macrocyclic compounds | |
CN108148076B (en) | Rapamycin C43-site guanidino derivative and preparation method and application thereof | |
WO2023115123A1 (en) | Crystalline intermediates | |
CZ20021361A3 (en) | Process for preparing oxazolines from tetrahydrofurans | |
IE64391B1 (en) | Process for preparing synergistins | |
EP3235810A1 (en) | Process for the preparation of bimatoprost |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11841039 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2818225 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13988265 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011841039 Country of ref document: EP |